Results 81 to 90 of about 1,753 (162)

Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant impacts on quality of life. Despite the effectiveness of biologics for moderate to severe AD, long-term treatment adherence can be challenging in clinical ...
Gold, LS, Casillas, M, Rand, K, Silverberg, J, Del Rosso, J, Akmaz, B, Puig, L, Irvine, A, Dossenbach, M, Foley, P, Gallo, G   +10 more
core   +1 more source

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids [PDF]

, 2018
Background: Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to many features of asthma.
Holweg, Cecile T.J., Korenblata, P., Anzures-Cabrera, J., Leshchenko, I., Korenblat, Philip, Putnam, W. S., Kerwin, Edwin, Martin, Carmen, Putnam, Wendy S., Yen, Karl, Governale, Laura, Anzures-Cabrera, Judith, Leshchenko, Igor, Olsson, Julie, Matthew, John G., Matthews, J. G., Martin, C., Holweg, C. T. J., Governale, L., Olsson, J., Kerwin, E., Yen, K.   +21 more
core  

Successful Lebrikizumab Therapy in Two Patients With Atopic Dermatitis Resistant to Multiple Therapies

JEADV Clinical Practice
The treatment landscape for moderate‐to‐severe atopic dermatitis (AD) has evolved significantly with the introduction of novel targeted therapies addressing specific pathogenic mechanisms of the disease.
Elena Ippoliti, Niccolò Gori, Benedetta Ambrosio, Giulia Coscarella, Maria Vittoria Cannizzaro, Ketty Peris   +5 more
doaj   +1 more source

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

Journal of Dermatological Treatment
Background Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch ...
Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Linda Stein-Gold   +9 more
doaj   +1 more source

Advances in Atopic Dermatitis Management: The Role of Lebrikizumab

Dermatologic Therapy
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus and eczematous lesions, significantly impacting patients’ quality of life. Current treatment options include topical therapies (e.g., corticosteroids, calcineurin inhibitors, and topical Janus kinase [JAK] inhibitors), phototherapy, and systemic ...
Saba Mushtaq, Hafsa Shuja, Hamza Yousuf Ibrahim, Syeda Farwa Zehra, Umer Wamiq, Muhammad Faisal, Fawaz Ur Rehman, Ayesha Abdullah, Ehsanullah Alokozay   +8 more
openaire   +1 more source

Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis

Frontiers in Medicine
IntroductionAtopic dermatitis (AD) is a chronic inflammatory skin condition affecting 5%−20% of children and 2%−10% of adults worldwide. Treatment for moderate-to-severe AD includes biologics like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors
Rose Alraddadi, Rose Alraddadi, Mulham Kalantan, Mulham Kalantan, Yara Aljefri, Yara Aljefri, Hadeel Maaddawi, Abdulrahman Alsamadani, Abdulrahman Alsamadani, Athoub Kadasa, Athoub Kadasa, Abdulrahman Softah, Abdulrahman Softah, Baraa Tabbakh, Baraa Tabbakh, Rahaf Alturkistani, Abdulhadi Jfri, Abdulhadi Jfri, Abdulhadi Jfri   +18 more
doaj   +1 more source

Lebrikizumab [PDF]

, 2020
openaire   +1 more source

Incidence of conjunctivitis adverse event in patients treated with biologics for atopic dermatitis: A systematic review and meta-analysis

JAAD International, 2023
Rose Alraddadi, MD, Abdulrahman H. Alsamadani, MD, Mulham A. Kalantan, MD, Yara E. Aljefri, MD, Hadeel A. Maaddawi, MD, Athoub N. Kadasa, MD, Rahaf F. Alturkistani, MD, Abdulhadi H. Jfri, MD, MSc   +7 more
doaj   +1 more source

Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis". [PDF]

Dermatol Ther (Heidelb)
Rand K, Gebauer K, Binamer Y, Cho YT, Papadimitropoulos M, Yang C, Agell H, Akmaz B, Seminario-Vidal L.   +8 more
europepmc   +1 more source

Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis. [PDF]

Patient Prefer Adherence
Soung J, Miller W, Jarell AD, Greenstein D, DeLuca-Carter L, Crane HM, Behling M, Duffy K, Pierce E, Shahriari M.   +9 more
europepmc   +1 more source